Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
<strong>Background<br></strong> Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms used in homologous and heterologous...
Main Authors: | Shaw, RH, Greenland, M, Stuart, AS, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJ, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Libri, V, Lillie, PJ, Morey, E, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Mary Ramsay, F, Read, RC, Hannah Robinson, RN, Screaton, GR, Singh, N, Turner, DP, Turner, PJ, Rachel White, RN, Nguyen-Van-Tam, JS, Liu, X, Snape, MD |
---|---|
Other Authors: | Com-COV2 Study Group |
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2023
|
Similar Items
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
by: Stuart, ASV, et al.
Published: (2021) -
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
by: Shaw, RH, et al.
Published: (2022) -
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
by: Liu, X, et al.
Published: (2021) -
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
by: Shaw, RH, et al.
Published: (2021) -
Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
by: Valente Pinto, M, et al.
Published: (2020)